Skip to content
Clinical Trials – home

Respiratory syncytial virus bronchitis

  • 2 clinical trials
Quick filters

2 Clinical trials

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Immune Response and Safety of RSVPreF3 Vaccine in Adults 18-49 at Risk for Respiratory Syncytial Virus Compared to Adults 60 and Older

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals
See all trials →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.